Genentech, a member of the Roche Group, has entered a global collaboration and licensing agreement with Duality Biotherapeutics, Inc. to develop a new generation of antibody-drug conjugates built around DualityBio’s DUPAC payload technology, putting more pharmaceutical capital behind the emerging effort to overcome resistance to today’s dominant ADC payloads. DualityBio will receive $45 million upfront and could collect more than $1 billion in aggregate development, regulatory and commercial milestones across the collaboration programs, alongside tiered royalties on annual net sales of approved products.
The August 28, 2026 agreement is notable because Genentech is not merely licensing an individual clinical-stage ADC. Instead, the Roche subsidiary is gaining exclusive worldwide rights to multiple potential programs generated from a payload platform intended to attack a weakness that could become increasingly important as antibody-drug conjugates move into earlier treatment settings: what happens after cancer cells stop responding to established payload classes. DualityBio will lead discovery and early global clinical development through Phase 1a before Genentech assumes responsibility for later development and commercialization.
Why is Genentech investing in a new antibody-drug conjugate payload platform?
An antibody-drug conjugate attempts to combine the targeting ability of a monoclonal antibody with the cell-killing potency of a cytotoxic payload. The antibody recognizes a selected antigen on tumor cells, the linker carries the payload through circulation, and the drug is designed to release its cytotoxic component after reaching the cancer cell or its surrounding tumor environment.
The concept has delivered major advances in oncology, but the success of individual ADCs has also concentrated the industry around several familiar payload mechanisms. Topoisomerase I inhibitors have become particularly prominent because they can generate strong antitumor activity across several solid tumors and can produce a useful bystander effect in heterogeneous cancers where not every cell expresses the target antigen equally.
That success creates its own problem. As topoisomerase-based ADCs move into earlier lines of treatment, a larger number of patients will eventually have tumors that progressed during or after exposure to that payload class. DualityBio says DUPAC was designed specifically around payloads with different antitumor mechanisms that could retain activity in tumors relatively insensitive or resistant to topoisomerase inhibitor payloads.
Genentech’s agreement therefore looks beyond the question of which antigen should be targeted next. It addresses the equally important question of what should actually be delivered after the antibody reaches the tumor.
How does DualityBio’s DUPAC technology differ from conventional ADC approaches?
DUPAC stands for DualityBio Unique Payload Antibody Conjugate and is one of four ADC technology platforms developed by DualityBio alongside DITAC, DIMAC and DIBAC. The DUPAC platform includes multiple payloads with distinct mechanisms of action, including candidates designated DUP5, DUP9 and DUP10.
DualityBio says the platform has been engineered around several common principles, including high potency, broad activity across tumor types, systemic stability, relatively rapid clearance of released payload and a bystander effect capable of attacking heterogeneous tumors. The company has presented preclinical results involving DUP5- and DUP9-based ADCs in tumor models that were relatively insensitive to topoisomerase inhibitor payloads, alongside non-human-primate tolerability work.
That distinction matters because resistance to an ADC can emerge at several levels. Cancer cells can reduce expression of the surface antigen, change internalization behavior, alter intracellular trafficking, become resistant to the payload’s mechanism or increase their ability to remove or neutralize the cytotoxic compound. Switching antibodies while repeatedly using a similar payload may therefore fail to solve every resistance mechanism.
A portfolio of payloads with substantially different mechanisms could allow developers to match not only the antibody to tumor biology but also the payload to a patient’s previous ADC exposure and resistance profile. That remains a development hypothesis rather than an established clinical advantage for DUPAC, but it explains why novel payload chemistry has become one of the most closely watched areas of the ADC field.
How will the Genentech and DualityBio collaboration work?
DualityBio will generate ADCs against oncology targets defined by Genentech and will conduct discovery and early global clinical development. Genentech receives an exclusive worldwide license to the resulting collaboration ADCs and will take sole responsibility for development and commercialization after Phase 1a.
The structure gives Genentech access to DualityBio’s payload chemistry without requiring the Roche subsidiary to build every discovery capability internally, while DualityBio retains a meaningful role through the first stage of human testing. The $45 million upfront payment is relatively modest compared with the more than $1 billion headline milestone potential, meaning a substantial portion of the economics depends on whether multiple programs successfully pass development and commercial thresholds.
For DualityBio, the arrangement also provides another external validation point for a company that has built multiple ADC platforms and is already conducting global multicenter studies across nearly 20 countries. The company reported that more than 3,500 patients have been enrolled across its clinical programs to date.
The significance is therefore broader than the immediate cash payment. A major oncology company is effectively placing a platform-level bet on DualityBio’s ability to generate payloads differentiated enough to justify new ADC programs in an increasingly competitive field.
Why is ADC resistance becoming a bigger pharmaceutical opportunity?
The first commercial wave of antibody-drug conjugates proved that targeted delivery could transform treatment in selected cancers. The next phase will increasingly involve patients who have already received one or more ADCs, creating a sequencing problem similar to what occurred with kinase inhibitors, hormonal agents and other targeted therapies.
If an individual has already progressed after a topoisomerase inhibitor ADC, physicians may eventually need to know whether the next ADC uses a different antigen, a different payload, a different linker technology or some combination of all three. This could turn payload mechanism into a clinically important treatment-selection variable rather than a largely technical characteristic discussed mainly by drug developers.
There is also a competitive reason for pharmaceutical companies to diversify. As successful targets such as HER2 attract numerous ADC programs, simply attaching another similar cytotoxic compound to another antibody may offer diminishing differentiation. Novel payloads provide another route to create intellectual property, expand efficacy into resistant tumors and potentially improve therapeutic index.
The challenge is that a powerful new payload is not automatically a better one. ADC developers must still balance potency with systemic toxicity, linker stability, off-target exposure and the pharmacokinetic behavior of metabolites released after the conjugate is broken down.
What should the oncology industry watch next?
The immediate question is which Genentech-selected targets enter the collaboration and how quickly the first program reaches human testing. Neither company disclosed the targets or the number of ADC candidates that could ultimately emerge, preserving considerable uncertainty around the scale and timing of the pipeline.
The more consequential question will take longer to answer: whether DUPAC payloads genuinely produce clinical responses in tumors that have progressed after topoisomerase-based ADC therapy. Preclinical resistance models can support a development rationale, but oncology history contains many mechanisms that appeared compelling before human trials and failed to produce sufficiently differentiated efficacy.
The Genentech agreement nevertheless signals where the ADC field is heading. As antibody-drug conjugates become established therapies rather than experimental exceptions, the industry must begin developing drugs for the post-ADC patient. The next major competitive advantage may therefore come not from building another version of the current generation, but from designing what physicians can use after that generation stops working.
